Diffusion-Weighted Magnetic Resonance Imaging Allows Noninvasive In Vivo Monitoring of the Effects of Combretastatin A-4 Phosphate after Repeated Administration
Open Access
- 1 August 2005
- Vol. 7 (8), 779-787
- https://doi.org/10.1593/neo.04748
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Cancer cells compress intratumour vesselsNature, 2004
- Combretastatin A4 Phosphate Has Tumor Antivascular Activity in Rat and Man as Demonstrated by Dynamic Magnetic Resonance ImagingJournal of Clinical Oncology, 2003
- Assessment of Pharmacodynamic Vascular Response in a Phase I Trial of Combretastatin A4 PhosphateJournal of Clinical Oncology, 2003
- Phase I Clinical Trial of Weekly Combretastatin A4 Phosphate: Clinical and Pharmacokinetic ResultsJournal of Clinical Oncology, 2003
- Early Detection of Response to Radiation Therapy in Patients With Brain Malignancies Using Conventional and High b-Value Diffusion-Weighted Magnetic Resonance ImagingJournal of Clinical Oncology, 2003
- Vascular targeting effect of combretastatin A‐4 phosphate dominates the inherent angiogenesis inhibitory activityInternational Journal of Cancer, 2003
- Diffusion MRI: A New Strategy for Assessment of Cancer Therapeutic EfficacyMolecular Imaging, 2002
- Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumour modelsInternational Journal of Cancer, 2002
- The biology of the combretastatins as tumour vascular targeting agentsInternational Journal of Experimental Pathology, 2002
- Vascular targeting of solid tumours: a major ‘inverse’ volume–response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomasEuropean Journal Of Cancer, 2000